StemCell Therapy

A fishing expedition 15 years ago off the west coast of Greenland led scientists to discover the world's oldest vertebrate, Greenland sharks. This species can live at least 250 years. Scientists see lifestyle and genetics as a possible cause, and gene therapy techniques help humans adopt the same longevity.

Danish marine biologist John Steffensen was on a fishing expedition 15 years ago when he spotted an unusual-looking shark that hung from the boat's edge. Greenland sharks are large, sluggish, and awkwardly proportioned sharks that roam the icy depths of the North Atlantic Ocean and the Gulf of Mexico.

Steffensen and his colleagues published their findings in a study titled "Eye Lens Radiocarbon Reveals Centuries of Longevity in the Greenland Shark(Somniosus microcephalus)," onSciencein 2016. Since then, this cadaverous shark has become a sensation, with scientists worldwide trying to unlock the secret of its longevity, noting that it could show humans how to live long.

(Photo: Wikimedia Commons)Close-up image of a Greenland shark taken at the floe edge of the Admiralty Inlet, Nunavut

According toAtlas Obscura, Greenland sharks were commercially hunted for their oil-rich livers during the first half of the 20th century. However, presently, fishers find them a nuisance since these species feed o valuable halibut. Sometimes, they also get tangled with fishnets that could damage equipment on deck if they could not find a way out.

Steffensen's interest in Greenland sharks peaked when he learned of the extreme longevity of the sharks. They tried scanning the sharks for signs of growth rings but failed and found no evidence of their age.

So, he consulted retired physicist Jan Heinemeier from Denmark's Aarhus University, who gave him the idea of dating eye lenses produced at birth and could be subjected to carbon dating.

The results were astounding, showing that Greenland sharks could live at least 272 years up to 512 years old. In thevideoby Wonder World, they discussed that the oldest Greenland shark was 512 years old found in the North Atlantic, which could also hold the record of being the oldest living vertebrate in the world.

The scientists at first could not believe their findings, questioning whether they have made a mistake or not. Another thing they observed is that older Greenland sharks grow at a slower rate than young ones. The largest they found was 16 feet long, but they could still grow up to 18 feet.

ALSO READ: Two Female Sharks Reproduce Offspring; Recorded as First Case of Asexual Reproduction in Italy

Finding out that there could be sharks swimming in the ocean born during the Renaissance period is extraordinary. Scientists have asked how these creatures could live that long. They believe it might be due to genetics and lifestyle.

According toNBC News, Greenland sharks' longevity might have to do with their extraordinary heart and unique immune systems. The sharks' hearts pump slowly by about one beat per 12 seconds, and they have been beating already for centuries. On the other hand, a human heart beats about once every second and gradually slows down as humans age.

Moreover, DNA sequencing of Greenland sharks shows that genetic mutations in them have given them an immune system that can stop cancer and other infectious diseases.

In the future, scientists hope to transplant the genes to humans to promote long life using gene therapy techniques. However, this technology is in its early years, and more studies are needed to be successful.

RELATED ARTICLE: Godzilla Shark From 300 Million Years Ago Finally Gets New Name, Classified as New Species

Check out more news and information on Sharksin Science Times.

Go here to see the original:
Greenland Sharks Live Hundreds of Years; Can These Sharks Teach Humans How to Live Long? - Science Times

You don't have to live in a blue zone to live over a century. "Blue zones" are known to have the densest population of people that live to be over 100located in five different communities around the world. And yet, while these communities are known for being the healthiest and living the longest, the truth is, you don't have to be a community member to reap the same benefits. While genetics do play a role in longevity, setting healthier habits also significantly increases your chances of living long enough to reach that three-digit number.

So what's their secret? If you were to place a microscope on these communities, you would notice that their diets include a variety of real, whole foods. They also focus on eating at the table, sharing meals with others, and regularly moving their bodies.

But what's exactly on their plates? We spoke with a few registered dietitians to look at some of the healthy eating habits that can help you to live over a century, and these tips line up closely with the type of lifestyles lived by those in blue zones. Here are the healthy eating habits you can incorporate into your life today in order to have a happier, healthier tomorrow. Then, be sure to check out our list of The 7 Healthiest Foods to Eat Right Now.

"It is well-known that fruit and vegetables are good for you, but it's important to remember that it's more than just that," says Amy Goodson, MS, RD, CSSD, LD. "Colorful fruits and veggies provide the body with various vitamins, minerals, antioxidants, and plant compounds that help the heart, the gut as well as keep your immune system strong and more! Each color of produce contains a different nutrient package."

RELATED:Get even more healthy eating tips straight to your inbox by signing up for our newsletter!

"While everyone's body and natural genetics are different, fueling your body appropriately is a crucial component if you would like to live over a century," says Ricci-Lee Hotz, MS, RDN at A Taste of Health, LLC and Expert at Testing.com. "Ensuring that you consume a varied diet with a range of different fruits, veggies, lean proteins, whole grain, high fiber carbs, and healthy fat, and balancing them appropriately at each meal and snack is crucial to make sure your body is getting everything it needs to function at its best. In addition, keeping your stress levels down (especially surrounding food) can always help your body stay as healthy as possible, too."

"Following a plant-based diet is one of the best possible dietary choices to live a life with greater quality and quantity," says Trista Best, MPH, RD, LD, and a registered dietitian at Balance One Supplements. "For many who turn to a plant-based diet, their goal is overall health and reduced risk of chronic disease, which culminates in longer life. Among the many benefits of a plant-based diet, including, heart health, weight loss, and diabetes prevention a new secondary benefit is emerging; reduced cancer risk."

Best points out research from the American Institute for Cancer Research which states that one of the best ways to prevent cancer is through dietary means. Focusing on nutrients like fiber, vitamins, minerals, and phytonutrients into your diet is key, and can be found in foods like vegetables, fruit, beans, grains, nuts, and seeds.

If going plant-based does not feel like something that is attainable for you, Best also recommends focusing on a flexitarian approach if you want to live over a century.

"For many, this can be a daunting task and a flexitarian approach may be the best option," she says. "Regardless of where you fall, reducing animal protein in your diet will improve your longevity."

Here are 10 Benefits of Eating a More Plant-Based Diet.

"The healthiest of people fill their plate with nutrient-rich foods like whole grains, fruits, vegetables, lean protein, dairy, and healthy fat, but they also allow for pleasure foods," says Goodson. "The key to a long, happy life is balance. The majority of the time, 80%, eat foods to fuel your body and keep it strong. Then 20% of the time enjoy vacations, holidays, and desserts with the people you love. It's the best plan for the body and the soul."

It's all about setting healthier habits for yourself! Here are5 Healthy Dessert Habits For A Flat Belly.

"It's important to not overeat," Rachel Paul, PhD, RD from CollegeNutritionist.com. "Overeating calories, even of healthier foods, leads to weight gain. Those with overweight or obese bodies are more likely to develop diseases such as diabetes, heart disease, and some cancers, which can lead to premature death."

One of the best ways to combat overeating is to start paying attention to your body's hunger and fullness clues, portioning out your meals, and setting specific times for meals and snacks throughout the day. Overeating and mindless snacking can easily come hand-in-hand, so it's important to set healthy snacking habits that will help you feel full, prevent overeating, and help you ultimately live over a century.

"As we age, we typically lose 2 to 3% muscle mass per decade," says Goodson. "That can lead to falls, bone breaks, and instability as we age. The key? Power up with lean protein at all meals and snacks. Protein helps and builds and repairs muscles helping to keep your body strong as you age. Including foods like lean beef, poultry, fish, eggs, dairy, beans, and legumes can all help you amp up your protein."

"As a dietitian, I'm always telling people to 'eat the rainbow' because all the different colored foods represent different phytonutrients that help keep us healthy as we age," says Mackenzie Burgess, RDN and recipe developer at Cheerful Choices. "One beneficial type of phytonutrient you'll find in colorful fruits, vegetables, and other plant foods are compounds called 'flavonoids.' In fact, recent research has proven these flavonoids to be helping in maintaining our brain health long-term. Flavonoid-rich foods include onions, berries, dark greens, herbs, broccoli, cauliflower, dark chocolate, soy, and citrus fruits."

To easily incorporate flavonoid-rich foods into your diet, Burgess says "For breakfast try mashing together berries and chia seeds to make your own jam. Then, for lunch, blend cauliflower into rice or find it in flatbread form to pair with your favorite protein. Finally, for dinner, try stirring extra onions and herbs into a one-pot curry."

"To keep our brains sharp and to prevent cognitive decline, what we eat can make a difference," says Lisa R. Young, PhD, RDN, author of Finally Full, Finally Slim and a member of our medical expert board. "Foods high in certain vitamins, antioxidants, and phytochemicals may help to boost brain health. Deep red foods such as tomatoes and watermelon contain the antioxidant lycopene which fights free radicals that come with aging. Leafy greens such as kale and spinach are rich in vitamins E and K which may prevent memory loss and help reduce our 'brain age.'"

Related:Why You Need Antioxidants In Your DietAnd How To Eat More Of Them

"As we age, our metabolism tends to slow down so it is important to watch calories and exercise more to avoid weight gain," says Young. "It turns out that maintaining a steady weight and avoiding yo-yo dieting is equally important. The centenarians from Okinawa, known to live long and healthy lives, were known to keep their calories down and their weight steady. Maintaining a healthy body mass index (BMI) has been associated with lower rates of heart disease and certain cancers."

For more, be sure to read our list of The 6 Best Diets That Will Make You Live Longer, Say Dietitians.

Link:
9 Healthy Eating Habits to Live Over A Century, Say Dietitians | Eat This Not That - Eat This, Not That

A former junior motorsport racer with multiple sclerosis who battled against the odds to receive experimental stem cell treatment in Panama in April is already noticing improvements in his condition.

Alister Bailey, 39, a former Barnes resident, travelled to the Stem Cell Institute with his wife Gemma, despite warnings they would not be let in to Panama due to coronavirus travel restrictions.

MS is an autoimmune disease that can affect the brain and spinal cord. Common symptoms include mobility problems, vision problems, muscle spasms, fatigue and speech difficulties.

Before Panama, Alister couldnt hold a cup of tea, but now his hands have stopped shaking and he can pour a drink without spilling it. He has also noticed an improvement in his eyesight.

Gemma said: This might seem trivial but its a huge physical change.Thats a really positive sign and certainly encouraging for us in terms of the next round.

We have seen some positive signs already which is amazing because we didnt really have any expectations this time round to be honest; it was more to stop the deterioration.

He really believes it will work and he feels something is happening.

The Baileys are currently fundraising to get Alister back to Panama for a second round of treatment in November.

The pair were supposed to fly out to Panama for the first round in January after raising 22,500, but coronavirus put a stop to those plans.

Travel restrictions meant they had to delay the trip until the end of April but, even then, it was not an easy ride.

Read below about their rollercoaster journey:

The pair opted for experimental mesenchymal stem cell therapy because treatment options for progressive MS are limited.

A year after he married Gemma, Alister started experiencing episodes where he wasnt able to walk and then he went blind for two days in 2012.

Since receiving his diagnosis, Alister has been on a drug for ten years to slow symptom progression. But Gemma said his condition has rapidly deteriorated in the past three years. While he does not use a wheelchair at home, he cannot walk any long distance unsupported.

She said: Theres no cure for progressive MS so this treatment in Panama is his only hope.

Alister didnt qualify for anything on the NHS which was pretty disheartening.

We have various doctor friends, some of them researching stem cell treatments for different illnesses but they said this is where medicine is going in the future.

The Stem Cell Institute administers mesenchymal stem cells (MSCs) which are recovered from donated umbilical cords and grown in labs.

MSCs are adult cells which can produce other cells like muscle. This is why researchers are interested in testing whether they can protect nerves from more damage and repair the original damage.

The Baileys are hoping to see the best benefits of the treatment after two or three rounds and have prepared themselves for potentially five visits.

They have planned fundraising events to get together the funds needed for November.

On 17 July, Alisters 67-year-old dad Chris took on the Surrey Hills Epic Off-Road Challenge which involves 125km of off-road mountain biking.

Gemma is organising a charity dinner and her friend Claire is running the Lulworth Cove Trail Challenge which involves running along the coastline.

Their friend Jonny Wright has already raised $14,400 as he prepares to cycle 2,500 miles from Maine to Florida in 30 days starting on 27 August.

Their hope is that the treatment will stimulate repair of the damaged tissues so that Alister can play football with his son again.

You can follow the familys journey on their Instagram page.

You can donate to their fundraiser here.

Credit for all photos: Gemma and Alister Bailey.

See the original post here:
Dad with multiple sclerosis who fought for treatment in Panama during Covid restrictions finds first round is 'reaping rewards' - South West Londoner

Multiple sclerosis is an autoimmune disease that can affect the brain and spinal cord, and it is estimated that 130,000 people in the UK have the condition.

There are drugs available to slow the onset of symptoms but treatment options for progressive MS are limited and there is currently no cure.

At the end of July, the US Food and Drug Administration authorised a Phase 2 clinical trial at Hope Biosciences Stem Cell Research Foundation in Texas.

The future of MS treatment is exciting; scientists think solutions for all types of MS could be in their late stage trials by 2025.

But what are the options for those living with progressive MS right now? Some are desperate to halt their symptom deterioration.

Increasingly, they are looking to experimental treatments like the one offered by Panamas Stem Cell Institute.

Alister Bailey and Liam Egalton both raised tens of thousands of pounds to travel to Panama for mesenchymal stem cell therapy. To find out about their turbulent journeys during the pandemic and learn more about ongoing MS treatment research projects, read the full story here:

https://swlondoner.shorthandstories.com/multiple-sclerosis-and-the-experimental-treatment-giving-families-hope/index.html

Read more from the original source:
Multiple sclerosis and the experimental treatment giving families hope - South West Londoner

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market by Product, by Material, by Application - Global Opportunity Analysis and Industry Forecast, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market is expected to reach USD 172.15 billion by 2030 from USD 13.96 billion in 2020, at a CAGR of 28.9%.

Companies Mentioned

Regenerative Medicine are used to regenerate, repair, replace or restore tissues and organs damaged by diseases or due to natural ageing. These medicines help in the restoration of normal cell functions and are widely used to treat various degenerative disorders such as cardiovascular disorders, orthopedic disorders and others.

The rising demand for organ transplantation and increasing awareness about the use of regenerative medicinal therapies in organ transplantation along with implementation of the 21st Century Cures Act, a U.S. law enacted by the 114th United States Congress in December 2016 are creating growth opportunities in the market. However, high cost of treatment and stringent government regulations are expected to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and RoW.

Key Topics Covered:

1. Introduction

2. Regenerative Medicine Market - Executive Summary

3. Porter's Five Force Model Analysis

4. Market Overview

4.1. Market Definition and Scope

4.2. Market Dynamics

5. Global Regenerative Medicine Market, by Product Type

5.1. Overview

5.2. Cell Therapy

5.3. Gene Therapy

5.4. Tissue Engineering

5.5. Small Molecules & Biologics

6. Global Regenerative Medicine Market, by Material

6.1. Overview

6.2. Synthetic Materials

6.3. Biologically Derived Materials

6.4. Genetically Engineered Materials

6.5. Pharmaceuticals

7. Global Regenerative Medicine Market, by Application

7.1. Overview

7.2. Cardiovascular

7.3. Oncology

7.4. Dermatology

7.5. Musculoskeletal

7.6. Wound Healing

7.7. Opthalomolgy

7.8. Neurology

7.9. Others

8. Global Regenerative Medicine Market, by Region

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia-Pacific

8.5. Rest of World

9. Company Profile

9.1. Integra Lifesciences Corporation

9.2. Abbvie Inc.

9.3. Merck Kgaa

9.4. Medtronic plc

9.5. Thermo Fisher Scientific Inc.

9.6. Smith+Nephew

9.7. Becton, Dickinson and Company

9.8. Baxter International Inc

9.9. Cook Biotech

9.10. Organogenesis Inc

For more information about this report visit https://www.researchandmarkets.com/r/nzud5i

Read the original:
Global Regenerative Medicine Market (2021 to 2030) - by Product, Material, Application and Region - ResearchAndMarkets.com - Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type, Cryogen Type, Application, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Freezers Segment to Contribute Major Share to Cryopreservation Equipment Market

Cryopreservation Equipment Market to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is estimated to grow at a CAGR of 9.9%

The report highlights the trends prevailing in the market along with the market drivers and deterrents. The factors such as growing acceptance for regenerative medicine and increasing needs of biobanking practices drive the market growth. However, stringent regulatory requirements hinder the cryopreservation equipment market growth.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.

Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.

Moreover, the US Food and Drug Administration (FDA) has approved blood-forming stem cells. The blood-forming stem cells are also known as hematopoietic progenitor cells that are derived from umbilical cord blood. The growing approvals for stem cell and gene therapies are eventually leading to the high demand for cryopreservation equipment. Following are a few instances of stem cell and gene therapies approved by the FDA and other regulatory bodies.

Based on type, the cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2020, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR during 2021-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

The COVID-19 pandemic has had a mixed impact on the cryopreservation equipment market. Restricted access to family planning services as well as diverted focus of people due to economic uncertainties and recession, and disturbed work-life balance have led to rise in egg and embryo freezing activities at fertility clinics during the pandemic.

As a result, the rising use of cryopreservation equipment is boosting the market growth. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means has substantially affected the distribution of cryopreservation equipment and other accessories.

Market players are launching new and innovative products and services to maintain their position in the cryopreservation equipment market. In May 2021, Stirling Ultracold has been acquired by BioLife Solutions, Inc for cell and gene therapies and the broader biopharma market. In return for all of Stirling's outstanding shares, BioLife issued 6,646,870 shares of ordinary stock.

Key Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Future Trends

The report segments the global cryopreservation equipment market as follows:

By Type

By Cryogen Type

By Application

By End User

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/tjgti5

Read the original post:
Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking...

Dublin, Aug. 27, 2021 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product, by Material, by Application - Global Opportunity Analysis and Industry Forecast, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market is expected to reach USD 172.15 billion by 2030 from USD 13.96 billion in 2020, at a CAGR of 28.9%. Regenerative Medicine are used to regenerate, repair, replace or restore tissues and organs damaged by diseases or due to natural ageing. These medicines help in the restoration of normal cell functions and are widely used to treat various degenerative disorders such as cardiovascular disorders, orthopedic disorders and others.

The rising demand for organ transplantation and increasing awareness about the use of regenerative medicinal therapies in organ transplantation along with implementation of the 21st Century Cures Act, a U.S. law enacted by the 114th United States Congress in December 2016 are creating growth opportunities in the market. However, high cost of treatment and stringent government regulations are expected to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and RoW.

The key players operating in the global regenerative medicine market include Integra Lifesciences Corporation, AbbVie Inc., Merck KGaA, Medtronic, Thermo Fisher Scientific Inc., Smith+Nephew, Becton, Dickinson and Company, Baxter International Inc, Cook Biotech, and Organogenesis Inc., among others.

Key Topics Covered:

1. Introduction

2. Regenerative Medicine Market - Executive Summary

3. Porter's Five Force Model Analysis

4. Market Overview4.1. Market Definition and Scope4.2. Market Dynamics

5. Global Regenerative Medicine Market, by Product Type5.1. Overview5.2. Cell Therapy5.3. Gene Therapy5.4. Tissue Engineering5.5. Small Molecules & Biologics

6. Global Regenerative Medicine Market, by Material6.1. Overview6.2. Synthetic Materials6.3. Biologically Derived Materials6.4. Genetically Engineered Materials6.5. Pharmaceuticals

7. Global Regenerative Medicine Market, by Application7.1. Overview7.2. Cardiovascular7.3. Oncology7.4. Dermatology7.5. Musculoskeletal7.6. Wound Healing7.7. Opthalomolgy7.8. Neurology7.9. Others

8. Global Regenerative Medicine Market, by Region8.1. Overview8.2. North America8.3. Europe8.4. Asia-Pacific8.5. Rest of World

9. Company Profile9.1. Integra Lifesciences Corporation9.2. Abbvie Inc.9.3. Merck Kgaa9.4. Medtronic plc9.5. Thermo Fisher Scientific Inc.9.6. Smith+Nephew9.7. Becton, Dickinson and Company9.8. Baxter International Inc9.9. Cook Biotech9.10. Organogenesis Inc

For more information about this report visit https://www.researchandmarkets.com/r/pl6r1p

See the original post:
Worldwide Regenerative Medicine Industry to 2030 - Featuring AbbVie, Medtronic and Thermo Fisher Scientific Among Others - GlobeNewswire

Regenerative medicine is a growing area of orthopedic treatment. Two orthopedic surgeons told Becker's what they found the most exciting about its development.

Ask Orthopedic Surgeons is a weekly series of questions posed to orthopedic surgeons around the country about clinical, business and policy issues affecting orthopedic care. We invite all orthopedic surgeon and specialist responses.

Next week's question: How will joint replacement surgical robots improve in the next 10 years?

Please send responses to Carly Behm at cbehm@beckershealthcare.com by 5 p.m. CDT Tuesday, Aug. 31.

Note: Responses were edited for style.

Question: What area of regenerative medicine holds the most promise for orthopedics?

Mihir Patel, MD. OrthoIndy (Indianapolis): Regenerative medicine is a truly exciting frontier in medicine. In orthopedics, bone graft implants and substitutes are helping patients return to normal activities. The implants can be used in index operations as well as revisions for a variety of orthopedic procedures including acute stress reactions, stress fractures not conducive to metal fixation, and subchondral procedures. The evolution of orthopedic implants from metal to plastic, and now bone is improving outcomes for patients and broadening our arsenal as surgeons to help patients heal. The bone graft substitutes are reducing comorbidities of graft harvesting. Additionally, they are adding to the value proposition for patients who may have difficulty healing bone defects, nonunions, and osteoporosis.

Much like advances in cancer therapies over the past decade, bone graft substitutes have the potential for personalized, targeted medicine for these diagnoses as biomarkers become more available to help clinicians really pinpoint at the molecular level why some heal more quickly than others. Finally, regenerative medicine includes mostly outpatient procedures with sterile kits that are easily transported, giving orthopedic surgeons the confidence in the manufacturing and sterilization process.

Jason Snibbe, MD. Snibbe Orthopedics (Los Angeles): I think the use of biologics from plasma and bone marrow have the most promise right now to help a variety of injuries in orthopedics. We are able to help people recover without surgery and use their own tissue to heal, specifically in labral tears of the hip and meniscus tears in the knee.

Read more from the original source:
2 surgeons weigh in on the most promising areas of regenerative medicine - Becker's Orthopedic & Spine

The University of California, Davis, set a new record for external research funding, receiving $968 million in awards in the fiscal year 2020-21, up $27 million from the previous record set last year. A major reason for this years growth was increased funding related to medicine and public health.

Professors Diana Farmer and Aijun Wang are collaborating to develop a stem cell treatment for spina bifida. (2019)

The School of Medicine received the largest increase in funding, up $92 million from the previous year, for a total of $368 million. Funding related to COVID-19 research totaled $42 million for the year. Studies in this area are providing critical insight into testing, vaccines, treatments and social impacts.

We are very proud of our researchers at the School of Medicine who rose to the challenge and expanded their groundbreaking work in the face of the pandemic, said Allison Brashear, dean of the UC Davis School of Medicine. All our research teams have shown great agility and collaboration across disciplines, quickly responding to emerging needs to prevent transmission and find treatments and vaccines to combat COVID-19, while also offering patients life-saving clinical trials in areas involving stem cell treatments, cancer and neuroscience, among many others.

Brashear noted that the School of Medicines clinical trials grew by 63% in the last year to $98 million.

The College of Agricultural and Environmental Sciences ($153 million), School of Veterinary Medicine ($83 million), College of Engineering ($80 million) and College of Biological Sciences ($58 million) rounded out the top five recipients.

This achievement reflects the unwavering commitment of our research community and their passion to address important societal needs during a year when operations were constrained due to the COVID-19 pandemic, Chancellor Gary S. May said. The societal impact of UC Davis research is far-reaching, spanning geographical boundaries and catering to diverse populations and needs.

The awards enable a broad range of research on topics including advancing human and animal health, protecting our planet and food supply and enabling a more resilient society.

The largest award, $51 million from the Department of Health and Human Services Centers for Disease Control and Prevention, went to Marc Schenker, distinguished professor of Public Health Sciences, to improve public health outcomes for all Californians by providing proper disease surveillance and prevention.

The federal government remains the largest provider of funding at $514 million, up $37 million from last year. The second leading source came from the state of California at $164 million, up $32 million. Funding from industry made up the third highest source, totaling $116 million, up $31 million.

UC Davis researchers received a total of 18 NSF CAREER Awards, a record for the university. These prestigious grants are offered to early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization.

Collaborative research bringing experts together from different fields of study continues to attract significant funding. These joint efforts often focus on addressing complex, large-scale challenges that require expertise from many perspectives.

We continue to see how multidisciplinary research provides a distinct advantage in tackling multifaceted issues, said Prasant Mohapatra, vice chancellor for Research at UC Davis. As one of the most academically comprehensive universities in the world, UC Davis offers a unique environment to solve these complex issues by bringing together experts from across our campuses.

Notable multidisciplinary awards include a $16 million grant from the National Institute of Mental Health for the UC Davis Conte Center to explore how infections in pregnancy lead to disorders in offspring. Principal investigators on this grant are Kimberly McAllister and Cameron Carter.

The Interdisciplinary Research and Strategic Initiatives division within the Office of Research offers support and resources to help teams advance their programs. Some of the notable interdisciplinary research projects include the work of Sheryl Catz, professor at the UC Davis Betty Irene Moore School of Nursing. Catz received $225,000 from the NIH National Cancer Institute for a project to improve the reach and effectiveness of smoking cessation services targeted to veterans living with HIV.

Diana Farmer, professor and chair in the Department of Surgery at UC Davis Health, also received $9 million from the California Institute for Regenerative Medicine (CIRM). Farmer is the principal investigator of the clinical trial, known formally as The CuRe Trial a cellular therapyfor in utero repair of myelomeningocele which uses stem cells before birth to treat the most serious form of spina bifida.

This story was originally written by Neelanjana Gautam and published here.

Note: Where funds are awarded up-front to cover several years, the money is counted in the first year the award was received. Incrementally funded awards are counted as authorized in each year. Reports are based on the principal investigators home school or college.

See more here:
UC Davis and the School of Medicine set new records in research funding - UC Davis Health

We live in a unique time when for the first time in human history there is a real opportunity to extend our lives dramatically. Recent scientific discoveries and technological breakthroughs that soon will translate into affordable and accessible life-extending tools will let us break the sound barrier of the current known record of 122 years. I am talking about breakthroughs in genetic engineering, regenerative medicine, healthcare hardware, and health data.

Very soon, slowing, reversing, or even ending aging will become a universally accepted ambition within the healthcare community. Technology is converging to make this a certainty. Developments in the understanding and manipulation of our genes and cells, in the development of small-scale health diagnostics, and in the leveraging of data for everything from drug discovery to precision treatment of disease are radically changing how we think about healthcare and aging.

When I speak of the Longevity Revolution, what I really mean is the cumulative effect of multiple breakthroughs currently underway across several fields of science and technology. Together, these parallel developments are forming the beginning of a hockey-stick growth curve that will deliver world-changing outcomes.

Completed in 2003, the Human Genome Project successfully sequenced the entire human genomeall 3 billion nucleotide base pairs representing some 25,000 individual genes. The project, arguably one of the most ambitious scientific undertakings in history, cost billions of dollars and took 13 years to complete. Today, your own genome can be sequenced in as little time as a single afternoon, at a laboratory cost of as little as $200.

The consequences of this feat are nothing short of revolutionary. Gene sequencing allows us to predict many hereditary diseases and the probability of getting cancer. This early benefit of gene sequencing became widely known when Angelina Jolie famously had a preventative double mastectomy after her personal genome sequencing indicated a high vulnerability to breast cancer. Genome sequencing helps scientists and doctors understand and develop treatments for scores of common and rare diseases. Along with advances in artificial intelligence, it helps determine medical treatments precisely tailored to the individual patient.

Longevity scientists have even identified a number of so-called longevity genes that can promise long and healthy lives to those who possess them. Scientists now understand far better than ever before the relationship between genes and aging. And while our genes do not significantly change from birth to death, our epigenomethe system of chemical modifications around our genes that determine how our genes are expresseddoes. The date on your birth certificate, it turns out, is but a single way to determine age. The biological age of your epigenome, many longevity scientists now believe, is far more important.

Best of all, however, science is beginning to offer ways to alter both your genome and epigenome for a healthier, longer life. New technologies like CRISPR-Cas9 and other gene-editing tools are empowering doctors with the extraordinary ability to actually insert, delete, or alter an individuals genes. In the not terribly distant future, we will be able to remove or suppress genes responsible for diseases and insert or amplify genes responsible for long life and health.

Gene editing is just one of the emerging technologies of the genetic revolution: Gene therapy works by effectively providing cells with genes that produce necessary proteins in patients whose own genes cannot produce them. This process is already being applied to a few rare diseases, but it will soon become a common and incredibly effective medical approach. The FDA expects to approve 10 to 20 such therapies by the year 2025.

Another major transformation driving the Longevity Revolution is the field of regenerative medicine. During aging, the bodys systems and tissues break down, as does the bodys ability to repair and replenish itself. For that reason, even those who live very long and healthy lives ultimately succumb to heart failure, immune system decline, muscle atrophy, and other degenerative conditions. In order to achieve our ambition of living to 200, we need a way to restore the body in the same way we repair a car or refurbish a home.

Several promising technologies are now pointing the way to doing just that. While it is still quite early, there are already a few FDA-approved stem cell therapies in the United States targeting very specific conditions. Stem cellscells whose job it is to generate all the cells, tissues, and organs of your bodygradually lose their ability to create new cells as we age. But new therapies, using patients own stem cells, are working to extend the bodys ability to regenerate itself. These therapies hold promise for preserving our vision, cardiac function, joint flexibility, and kidney and liver health; they can also be used to repair spinal injuries and help treat a range of conditions from diabetes to Alzheimers disease. The FDA has approved 10 stem cell treatments, with more likely on the way.

Its one thing to replenish or restore existing tissues and organs using stem cells, but how about growing entirely new organs? As futuristic as that sounds, it is already beginning to happen. Millions of people around the world who are waiting for a new heart, kidney, lung, pancreas, or liver will soon have their own replacement organs made to order through 3D bio-printing, internal bioreactors, or new methods of xenotransplantation, such as using collagen scaffoldings from pig lungs and hearts that are populated with the recipients own human cells.

Even if this generation of new biological organs fails, mechanical solutions will not. Modern bioengineering has successfully restored lost vision and hearing in humans using computer sensors and electrode arrays that send visual and auditory information directly to the brain. A prosthetic arm developed at Johns Hopkins is one of a number of mechanical limbs that not only closely replicate the strength and dexterity of a real arm but also can be controlled directly by the wearers mindjust by thinking about the desired movement. Today, mechanical exoskeletons allow paraplegics to run marathons, while artificial kidneys and mechanical hearts let those with organ failure live on for years beyond what was ever previously thought possible!

The third development underpinning the Longevity Revolution will look more familiar to most: connected devices. You are perhaps already familiar with common wearable health-monitoring devices like the Fitbit, Apple Watch, and ura Ring. These devices empower users to quickly obtain data on ones own health. At the moment, most of these insights are relatively trivial. But the world of small-scale health diagnostics is advancing rapidly. Very soon, wearable, portable, and embeddable devices will radically reduce premature death from diseases like cancer and cardiovascular disease, and in doing so, add years, if not decades, to global life expectancy.

[Photo: BenBella Books]The key to this part of the revolution is early diagnosis. Of the nearly 60 million lives lost around the globe each year, more than 30 million are attributed to conditions that are reversible if caught early. Most of those are noncommunicable diseases like coronary heart disease, stroke, and chronic obstructive pulmonary disease (bronchitis and emphysema). At the moment, once you have gone for your yearly physical exams, stopped smoking, started eating healthy, and refrained from having unprotected sex, avoiding life-threatening disease is a matter that is largely out of your hands. We live in a world of reactive medicine. Most people do not have advanced batteries of diagnostic tests unless theyre experiencing problems. And for a large percentage of the worlds population, who live in poor, rural, and remote areas with little to no access to diagnostic resources, early diagnosis of medical conditions simply isnt an option.

But not for long. Soon, healthcare will move from being reactive to being proactive. The key to this shift will be low-cost, ubiquitous, connected devices that constantly monitor your health. While some of these devices will remain external or wearable, others will be embedded under your skin, swallowed with your breakfast, or remain swimming through your bloodstream at all times. They will constantly monitor your heart rate, your respiration, your temperature, your skin secretions, the contents of your urine and feces, free-floating DNA in your blood that may indicate cancer or other disease, and even the organic contents of your breath. These devices will be connected to each other, to apps that you and your healthcare provider can monitor, and to massive global databases of health knowledge. Before any type of disease has a chance to take a foothold within your body, this armory of diagnostic devices will identify exactly what is going on and provide a precise, custom-made remedy that is ideal just for you.

As a result, the chance of your disease being diagnosed early will become radically unshackled from the limitations of cost, convenience, and medical knowledge. The condition of your body will be maintained as immaculately as a five-star hotel, and almost nobody will die prematurely of preventable disease.

There is one final seismic shift underpinning the Longevity Revolution, and its a real game-changer. Pouring forth from all of these digital diagnostic devices, together with conventional medical records and digitized research results, is a torrent of data so large it is hard for the human mind to even fathom it. This data will soon become grist for the mill of powerful artificial intelligence that will radically reshape every aspect of healthcare as we know it.

Take drug discovery, for instance. In the present day, it takes about 12 years and $2 billion to develop a new pharmaceutical. Researchers must painstakingly test various organic and chemical substances, in myriad combinations, to try to determine the material candidates that have the best chance of executing the desired medical effect. The drugs must be considered for the widest range of possible disease presentations, genetic makeup, and diets of targeted patients, side effects, and drug interactions. There are so many variables that it is little short of miraculous that our scientists have done so much in the field of pharmaceutical development on their own. But developing drugs and obtaining regulatory approval is a long and cash-intensive process. The result is expensive drugs that largely ignore rarer conditions.

AI and data change that reality. Computer models now look at massive databases of patient genes, symptoms, disease species, and millions of eligible compounds to quickly determine which material candidates have the greatest chance of success, for which conditions, and according to what dose and administration. In addition to major investments by Big Pharma, there are currently hundreds of startups working to implement the use of AI to radically reshape drug discovery, just as we saw happen in the race to develop COVID-19 vaccines. The impact that this use of AI and data will have on treating or even eliminating life-threatening diseases cannot be overstated.

But that is not the only way that artificial intelligence is set to disrupt healthcare and help set the Longevity Revolution in motion. It will also form the foundation of precision medicinethe practice of custom-tailoring health treatments to the specific, personal characteristics of the individual.

Today, healthcare largely follows a one-size-fits-all practice. But each of us has a very unique set of personal characteristics, including our genes, microbiome, blood type, age, gender, size, and so on. AI will soon be able to access and analyze enormous aggregations of patient data pulled together from medical records, personal diagnostic devices, research studies, and other sources to deliver highly accurate predictions, diagnoses, and treatments, custom-tailored to the individual. As a result, healthcare will increasingly penetrate remote areas, becoming accessible to billions of people who today lack adequate access to medical care.

I predict that the development of AI in healthcare will change how we live longer, healthier lives as radically as the introduction of personal computers and the internet changed how we work, shop, and interact. Artificial intelligence will eliminate misdiagnosis; detect cancer, blood disease, diabetes, and other killers as early as possible; radically accelerate researchers understanding of aging and disease; and reestablish doctors as holistic care providers who actually have time for their patients. In as little as 10 years time, we will look back at the treatment of aging and disease today as quite naive.

The Longevity Revolution lives not in the realm of science fiction but in the reality of academic research laboratories and commercial technology R&D centers. The idea of aging as a fixed and immutable quality of life that we have no influence upon is ready to be tossed into the dustbin of history.

Sergey Young is a renowned VC, longevity visionary, and founder of the $100 million Longevity Vision Fund. This is an adapted excerpt from The Science and Technology of Growing Young, with permission by BenBella Books.

View original post here:
These 4 tech breakthroughs could help end aging - Fast Company

The global Human Embryonic Stem Cells (HESC) Market has been comprehensively analyzed and the results are presented in the market report published. The market concentration that is currently occupied by the Human Embryonic Stem Cells (HESC) market and an overview of the Human Embryonic Stem Cells (HESC) manufacturing industry is extensively researched in the report. An analysis of the collected data is used to reveal the market revenue earned by the different companies operating in the Human Embryonic Stem Cells (HESC) industry.

The global Human Embryonic Stem Cells (HESC) market depends on different factors that can either be a positive influence on the global market or cause the market to decline. The factors are identified and are categorized based on the effect that they can have on the market. The various factors are identified across all market segments and the different regions that are mentioned in the report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures): About Us: https://www.datalibraryresearch.com/sample-request/human-embryonic-stem-cells-hesc-market-2728?utm_source=unlvrebelyell&utm_medium=41

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Human Embryonic Stem Cells (HESC) market.

Some of The Companies Competing in The Human Embryonic Stem Cells (HESC) Market are Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics Inc., BD Biosciences, Cell Cure Neurosciences Ltd. (Israel),Cellular Dynamics International,GE Healthcare (UK), MilliporeSigma, PerkinElmer Inc., Reliance Life Sciences Ltd. (India),Research and Diagnostics Systems Inc., SABiosciences Corp.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Human Embryonic Stem Cells (HESC) market. All findings and data on the global Human Embryonic Stem Cells (HESC) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Human Embryonic Stem Cells (HESC) market available in different regions and countries.

Market Analysis, Insights and Forecast By Type

Totipotent Stem Cell Pluripotent Stem Cell Unipotent Stem Cell

Market Analysis, Insights and Forecast By Application

Regenerative medicine Stem cell biology research Tissue engineering Toxicology testing

Do You Have Any Query Or Specific Requirement? Ask to Our IndustryExpert@ https://www.datalibraryresearch.com/enquiry/human-embryonic-stem-cells-hesc-market-2728?utm_source=unlvrebelyell&utm_medium=41

The study objectives of this report are:

To study and analyze the global Human Embryonic Stem Cells (HESC) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2028.

To understand the structure of Human Embryonic Stem Cells (HESC) market by identifying its various subsegments.

Focuses on the key global Human Embryonic Stem Cells (HESC) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Human Embryonic Stem Cells (HESC) with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Human Embryonic Stem Cells (HESC) submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:

Data Library Research is a market research company that helps to find its passion for helping brands grow, discover, and transform. We want our client to make wholehearted and long term business decisions. Data Library Research is committed to deliver their output from market research studies which are based on fact-based and relevant research across the globe. We offer premier market research services that cover all industries verticals, including agro-space defense, agriculture, and food, automotive, basic material, consumer, energy, life science, manufacturing, service, telecom, education, security, technology. We make sure that we make an honest attempt to provide clients an objective strategic insight, which will ultimately result in excellent outcomes.

Contact Us:Rohit Shrivas,Senior Manager International Sales and MarketingData Library Researchinfo@datalibraryresearch.comPh: +13608511343 (US)www.datalibraryresearch.com

Go here to read the rest:
Human Embryonic Stem Cells (HESC) Market Updates to 2021: Brief, Trends, Applications, Types, Research, Forecast to 2028 UNLV The Rebel Yell - UNLV...

INTRODUCTION Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry.

New York, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical Regions - Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06130492/?utm_source=GNW In fact, in February 2021, the USFDA approved Breyanzi, a CAR-T cell-based therapy, developed by Bristol Myers Squibb, which is designed to treat relapsed or refractory large B-cell lymphoma. According to a recent report (published by The Alliance for Regenerative Medicine), over 1,200 clinical trials, focused on the evaluation of cell, gene and tissue-based therapies, are currently being conducted by over 1,000 organizations (including academic institutions), worldwide. Further growth of the market is primarily hindered by the limited availability of expertise, lack of specialized infrastructure to produce cell-based therapies, and several product development and manufacturing related challenges. With a sufficient body of evidence, validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders in this industry segment has now shifted to optimizing the cell therapy manufacturing process. Moreover, as more big pharma players enter this field of research, there is likely to be a substantial rise in the cell therapy manufacturing demand, as the proprietary product candidates of these large companies mature and need to be mass produced. In order to address the concerns related to manufacturing, several cell therapy developers (including the larger companies) have turned to contract manufacturing organizations (CMOs).

The cell therapy manufacturing service landscape features a mix of industry players (including well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that innovator companies that have the required capabilities and facilities to produce cell-based therapies for in-house requirements, also offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities). Further, in order to make cell therapies more affordable, several stakeholders are integrating various degrees of automation to cut down on labor costs and also improve process scalability. This specialty services industry has witnessed significant partnership activity over the past few years, with several companies being acquired by the larger firms, in efforts to grow and consolidate their capabilities in this space. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the cell production process, we believe that the market will witness significant growth in mid-long term.

SCOPE OF THE REPORT The Cell Therapy Manufacturing Market (4th Edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA) - Industry Trends and Global Forecasts, 2021-2030 report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes: A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), as well as location of headquarters and their respective manufacturing facilities. An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2016-2021, based on several relevant parameters, such as year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken). An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021, based on several relevant parameters, such as the year of agreement, type of partnership model adopted, type of cell and scale of operation. A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured. Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions. An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific). An in-depth analysis of cell therapy manufacturers using three versatile representations, namely [A] a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cell manufactured, scale of operation and purpose of production, [B] a logo landscape, based on the type of cell manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific), and type and size of organization (non-industry players, and small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical location of cell therapy manufacturing facilities of both industry and non-industry stakeholders. A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers while determining the price of their proprietary offerings. An elaborate discussion on the role of automation technologies in improving the current manufacturing methods, along with a comparative (qualitive) analysis of cost differences between manual and automated processes. A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO. A discussion on cell therapy manufacturing regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to manufacturing facilities by important regulatory bodies across the globe. Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile includes an overview of the company / organization, information on its manufacturing facilities, service portfolio, recent partnerships and an informed future outlook. A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industrys evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics. Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such products, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of cell therapy (T cell therapies, dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific, Latin America and MENA). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals: Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics) Gilles Devillers (General Manager, Bio Elpida) Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies) Arik Hasson (Executive VP Research and Development, Kadimastem) Fiona Bellot (Business Development Manager, Roslin CT) David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR) Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi) Tim Oldham (Chief Executive Officer, Cell Therapies) Gerard MJ Bos (Chief Executive Officer, CiMaas)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade? What is the current, installed contract manufacturing capacity for cell therapies? What are the key parameters governing the price of cell therapies? What are the key recent developments (such as partnerships and expansions) in this industry? What kind of partnership models are commonly adopted by stakeholders engaged in this domain? What are the different initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past? What different types of automated technology platforms available for the development and manufacturing of cell therapies? Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world? What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies? How is the current and future market opportunity likely to be distributed across key market segments?

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various emerging trends in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market, gathered from various secondary and primary sources of information.

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to cell-based therapies and ATMPs. It further includes a detailed discussion on the manufacturing process of cell-based therapies, and associated challenges, along with highlighting the applications of currently approved products. Additionally, it highlights information on the different manufacturing models (centralized and decentralized) that are being used for the production of cell-based therapies, as well as their associated advantages and disadvantages. Furthermore, it features details related to the scalability of cell-based therapies. The chapter also includes a brief overview of the role of automation and the need for effective supply chain management for cell-based therapies.

Chapter 4 features a detailed list of all the industry, as well as non-industry players that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of cell manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), as well as location of headquarters and their respective manufacturing facilities.

Chapter 5 features a detailed discussion on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe, Japan and China. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations located across various geographies, specifically in the US.

Chapter 7 discusses the role of automation technologies in optimization of current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.

Chapter 8 features detailed profiles of industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, recent partnerships and an informed future outlook.

Chapter 9 features profiles of non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on its service portfolio and manufacturing facilities.

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.

Chapter 11 features an analysis of the various partnerships and collaborations that have been inked amongst players engaged in this domain, between 2016-2021 (till February). It includes a brief description on the various types of partnership models that are employed by stakeholders in this market, and an analysis on the trend of partnerships. It also includes analyses based on year of agreement, type of partnership, scale of operation, type of cell manufactured and most active players. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals. Further, the chapter features an analysis of the various acquisitions that have taken place in this domain, highlighting geographical activity. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain.

Chapter 12 presents detailed analysis on the expansions that have taken place in the cell therapy manufacturing industry, since 2016. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances were analyzed based on various parameters, including year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).

Chapter 13 provides a detailed analysis of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.

Chapter 14 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small, mid-sized and large companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, Europe and Asia Pacific) and company size (small, mid-sized and large organizations).

Chapter 15 features a detailed analysis of the annual demand for cell therapies (in terms of number of patients), considering various relevant parameters, such as target patient population, dosing frequency and dose strength of the approved cell therapies, as well as those therapies that are currently being evaluated in clinical trials. The demand analysis has been segmented across different types of cell therapies (including CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells, tumor cells and stem cells), scale of operation (clinical and commercial) and regions (North America, Europe and Asia Pacific).

Chapter 16 highlights our views on various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches adopted by manufacturers to decide the price of its proprietary products.

Chapter 17 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 18 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of [A] type of cell therapy (T cell therapies, dendritic and tumor cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific and Latin America and MENA).

Chapter 19 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cell manufactured, scale of operation and purpose of production (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cell manufactured (immune cells and stem cells), geographical regions (North America, Europe and Asia Pacific) and the type / size of organization (non-industry, small, mid-sized and large companies). The chapter also comprises of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 20 provides a discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall cell therapy manufacturing industry.

Chapter 21 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cell therapy manufacturing market.

Chapter 22 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 23 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Gilles Devillers (General Manager, Bio Elpida), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Arik Hasson (Executive VP Research and Development, Kadimastem), Fiona Bellot (Business Development Manager, Roslin CT), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi), Tim Oldham (Chief Executive Officer, Cell Therapies) and Gerard MJ Bos (Chief Executive Officer, CiMaas).

Chapter 24 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 25 is an appendix, which contains a list of companies and organizations mentioned in this report.Read the full report: https://www.reportlinker.com/p06130492/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See the article here:
Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical...

NASHVILLE, Tenn., Aug. 25, 2021 /PRNewswire/ --Cryoport, Inc.(NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.

Cryoport and MLC will partner to create synergistic value by leveraging each other's global logistics networks. The partnership will provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. MLC has chosen to adopt Cryoport's unique and proprietary temperature-controlled and traceability solutions to meet the increasing demand for cell and gene therapy supply chain solutions and to strengthen its logistics capabilities.

Mr. Masao Fujikura, President of MLC said, "This strategic alliance will strengthen our ultra-low temperature-logistics services for our valued customers both domestically and internationally, utilizing Cryoport's proprietary technologies for cell and gene materials."

Jerrell Shelton, CEO of Cryoport, said, "This strategic alliance furthers our expansion strategy in the Asia-Pacific ("APAC") region. MLC and Cryoport will encourage the use of each other's network, infrastructure, knowledge and resources to enhance each other's operational performance and to generate value for customers in Japan and overseas to meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years. Combining both companies' strengths is expected to realize reliable and seamless distribution services for biopharmaceutical and pharmaceutical companies in Japan and the APAC region."

As of June 30, 2021, Cryoport supported 561 clinical trials in regenerative medicine globally, 29 of which are in the APAC region. In addition, a number of therapies supported by Cryoport have recently been approved in the APAC region, including Novartis' commercial therapy KYMRIAH, which is approved in Japan, Singapore and Australia and Bristol Myers Squibb's commercial therapy BREYANZI, which was approved in Japan. Cryoport is continuing to build out its position to support the growing number of commercial therapies in anticipation of the next wave of expected commercial approvals in the APAC region.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions and services, serving the Biopharma, Reproductive Medicine, and Animal Health markets. Through its family of companies, Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE, Cryoport provides strategic solutions that support the growing needs of these markets.

Cryoport's mission is to support life and health on earth through its advanced technologies, global supply chain network and dedicated scientists, technicians and supporting teams of professionals. Cryoport serves clients in life sciences research, clinical trials, and product commercialization. We support the creation of life, the sustaining of life and life-saving advanced cell and gene therapies in over 100 countries around the world. For more information, visit http://www.cryoport.com or follow @cryoport on Twitter at http://www.twitter.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, plans, strategy, acquisitions, including CRYOPDP and MVE Biological Solutions, financial results and financial condition. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the three and twelve months ended December 31, 2020 and any subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-and-mitsubishi-logistics-corporation-partner-to-bring-temperature-controlled-supply-chain-solutions-to-asia-pacific-301362330.html

SOURCE Cryoport, Inc.

See the original post here:
Cryoport and Mitsubishi Logistics Corporation Partner to Bring Temperature-Controlled Supply Chain Solutions to Asia-Pacific - Gallatin News

The word nano refers to the length scale (one nanometre is one-billionth of a metre) that is one thousand times smaller than the micro scale, the scale that was traditionally associated with the electronics industry. Viruses and DNA are examples of natural objects on the nano scale; in contrast a human cell can appear enormous.

The term nanotechnology refers to the engineering, measurement and understanding of nano-scaled materials and devices. Manipulating matter atom by atom and creating features on the atomic or nano scale is now a proven technology and there is an ever growing catalogue that utilises nanotechnology.

Nanotechnology represents an entire scientific and engineering field, broadly within Materials Science and Engineering, and not just a single product or even group of products. As a consequence of this there are several different types of nanotechnology, and many applications associated with each type. There are also several other types of nano-sized objects which exist in our environment, both natural and unnatural such as films and coatings, embedded nanotechnology, biologically natural, biological nanotechnology, natural particles, manufactured particles, nano-electrical mechanical systems.

Building on current nanotechnology-enabled applications in areas as diverse as consumer electronics, medicine, energy, water purification, aerospace, automotive, infrastructure, sporting goods, textiles, and agriculture, the nanotechnology research underway today will enable entirely new capabilities and products. Nanotechnology also underpins key industries of the future. For example, new architecture and paradigms exploiting nanotechnology are providing the foundation for artificial intelligence (AI), quantum information science (QIS), next-generation wireless communications, and advanced manufacturing.

While advances in modern electronics have long been at the nanoscale, new nanomaterials and designs will ensure the continued strength of the semiconductor industry, which powers computing, e-commerce, and national security. Nanotechnology also enables the rapid genomic sequencing and sensing required to advance medicine and biotechnology. Nanotechnology R&D has enabled early detection of emerging diseases and will lead to the treatments of the future. Past investments in nanotechnology research and development have provided a foundation to support the response to the Covid-19 pandemic. Nanotechnology-enabled applications include vaccines, sensors, masks, filters, and antimicrobial coatings.

Examples of nanotechnology innovations are: a highly sensitive wearable gas sensor; nanoparticles absorbed by plants to deliver nutrients; durable, conductive yarns made with MXene; electrodes that incorporate nanoparticles and enable the conversion of sunlight to hydrogen fuel; nano-engineered pores in a membrane for water filtration; drug-loaded nano particles carried by red blood cells; and the first programmable memristor computer, enabling low-power AI applications. Nanotechnology advances are impacting a variety of other sectors including consumer electronics, aerospace, automotive, infrastructure, sporting goods, and agriculture.

Research Infrastructure

The research infrastructure, including physical and cyber resources as well as education and workforce development efforts, is critical to support the entire funding ecosystem (National Nanotechnology Initiative), and agencies will continue to invest in these important areas. Agencies use a wide variety of mechanisms to support the research infrastructure, including Centre grants, instrumentation development or acquisition programmes, training grants, fellowships, and collaborative programmes that support workforce development.

Career opportunities

The scope and application of nanotechnology is tremendous. Indian engineering and science graduates are increasingly opting for nanotechnology. Right from medicine, pharmaceuticals, information technology, electronic, opto-electronics, energy, chemicals, advanced materials to textiles, nanotechnology has its applications. Nanotechnology provides job opportunities in health industry; pharmaceutical industry; agriculture industry; environment industry; food and beverage industry as well in government and private research institutes.

Skills

One needs to have a diehard passion for research, especially to find out new structures in the field of nanotechnology. It is important to have sound analytical skills, along with a scientific bent of mind. Analysing and interpreting skills are a necessity in this field and also to accept failures in experiments as a challenge. Other necessary skills which are required are: Good mathematical and computer programming skills; adequate laboratory training for expert handling of advanced equipment; ability to learn and adopt new techniques; have a systematic way of working; a natural propensity for research work; keep track of the latest scientific news, books and research magazines; a good background of physics, chemistry, medicine, electronics and biotechnology

Job Prospects

A lot of job opportunities and a research career exists in the areas of nano-device, nano-packaging, nano-wires, nano-tools, nano-biotechnology, nano-crystalline materials, nano-photonics and nano-porous materials to name a few. It is estimated that around three million nanotechnology skilled workforce will be required worldwide by 2021. Many government institutes and Indian industries have focused on nano-materials. It is also estimated nano-technology will create another five million jobs worldwide in support fields and industries. A professional in the field of nanotechnology can easily find lucrative jobs in most of fields.

Since nanotechnology is a special branch that essentially combines physics, chemistry, biology, engineering and technology, it is opening up job prospects for students specialising in these subjects. The career opportunities in the fields of nanoscale science and technology are expanding rapidly, as these fields have increasing impact on many aspects of our daily lives.

A professional in the field of nanotechnology can easily find viable career opportunities in various sectors. They can work in the field of nano-medicine, bio-informatics, stem cell development, pharmaceutical companies, and nano toxicology and nano power generating sectors.

The major areas for the development of applications involving nanotechnology are medical and pharmaceuticals, information technology, electronics, magnetics and opto-electronics, energy chemicals, advanced materials and textiles.

Nanotechnology has varied applications in drug delivery to treat cancer tumours (without using radiotherapy and chemotherapy), solar energy, batteries, display technologies, opto-electronic devices, semiconductor devices, biosensors, luminous paints, and many others. A major challenge in this emerging field is the training for a new generation of skilled professionals.

An abundance of job opportunities awaits candidates with an MTech in Nanotechnology from India and abroad. Indian industry has focused on nanomaterials and many scientific institutions have started research and development activities in the field. The CSIR has set up 38 laboratories, across the country, to carry out research and development work in this field. Those with a PhD in Nanotechnology will have vibrant opportunities in the R&D sectors.

It is a perfect career for those who have a scientific bent of mind and a passion for studying and experimenting with the minutest molecules. Students with a science and engineering background and even mathematics with a physics background can pursue Nanotechnology as a career. Candidates with MTech in Nanotechnology are in great demand both in India and abroad.

(The writer is Associate Professor, Department of Physics and Nanotechnology, SRM University)

Read this article:
Nanotech opens up job options in variety of industries - BL on Campus

Dr Chris Aukland BVSc VetMFHom MRCVS, Head of Livestock Health Programmes, Whole Health Agriculture, discusses homeopathy.

Chris leads the farmer education and support team at Whole Health Agriculture (WHAg). They offer training and support to help farmers develop skills to create resilient natural health and longevity in their livestock.

Chris has over 30 years experience in holistic veterinary practice and combines his work at WHAg with small animal surgery, ensuring he keeps up with the latest advances in alternative and conventional veterinary practice.

Dr CA: Homeopathy is an established system of medicine that supports the individuals own healing process, stimulating a state of dynamic homeostasis (or optimum balance), thereby minimising susceptibility to disease and fostering good health.

Homeopathy works by reminding the bodys natural healing mechanisms of what needs to be done to get back into a state of balance.

Often termed nano-medicine, homeopathy uses ultra-dilute substances to individualise treatment.

The symptoms presented by a sick animal or person are matched to the symptom picture of various remedies, choosing the remedy which is the closest match.

For example, caffeine can make us more alert. However, too much caffeine in some people can provoke sleeplessness, restlessness, anxiety and inability to focus.

Working on the homeopathic principle of treating like-with-like for somebody experiencing these symptoms perhaps due to worry or stress.

The best match might be the homeopathic remedy Coffea (produced from coffee), which has a symptom picture of sleeplessness, anxiety, restlessness and an inability to focus.

We have seen increasing demand for training and ongoing support from farmers, particularly over the last five years.

Our training webinars sell out. We are close to launching a membership and online learning platform developed to meet needs and support farmers no matter where they are in the world.

There appears to have been a quiet underground movement for some years. Suddenly, it is becoming more mainstream. Interest has always spread through word of mouth farmers trust farmers; if they say something is working, it creates demand.

A question to which we also wanted to know the answer!

We recently conducted a survey into the use of CAM (Complementary & Alternative Methods /Products/Medicines) among farmers to find out what they were using and why.

221 farmers, mainly from UK and Ireland, responded, the majority, 88%, of which used homeopathy. We looked at (among other things) specific markers based on figures that farmers are required to record.

Of all farmers who responded, 66% reported lower vet and medicine costs, and 65% responded that their use of CAMs has resulted in or contributed to zero, low or reduced antibiotic usage.

40% reported zero, low or reduced wormer usage and 36% reported reduced frequency or severity of lameness. One third reported increased financial profitability of the farm.

Of the 70 commercial dairy farmers who responded:

Also highly noteworthy is that 69% of dairy farmers reported fewer cases of milk withdrawal, and over half noted less frequent/severe mastitis and lower cell counts.

52% of dairy farmers have seen increased financial profitability of the farm.

Homeopathy is particularly useful because there is no risk of:a) Toxic side-effects,b) Drug residues, so no withdrawal period,c) Can help farmers reduce reliance on antibiotics

It can mitigate stress in routine events where conventional veterinary options have little to offer; events that we take for granted, such as weaning, tail ringing, castration, routine examination, separation etc. which can result in loss of condition or production.

A sick animal is an expensive animal. It can also improve herd vitality so that they are more resistant to infectious disease, parasites, etc. and animals thrive better.

Farmers also use homeopathy for infections. The following slide is taken from our survey and shows responses to the question: What conditions have you treated successfully without antibiotics? The dark blue bar shows the responses for homeopathy.

NB: The use of homeopathy should NEVER replace the vet. Our advice is always based on a holistic traffic-light triage. For any problem:

Look at the RED level first and for any serious condition, contact your vet as usual.

Then look at the GREEN level; this is your husbandry level. Can you mitigate any potential maintaining causes such as draughty barns, a change in feed, stress to the animal?

Finally, you can address the AMBER level and look at homeopathic and other natural medicine options.

In the UK, it is illegal to treat TB, which is a notifiable disease. As such, homeopathy should never be used to treat TB.

Always be aware of the local regulations. For any farm, we want all livestock to be as healthy and naturally resilient as possible.

Used well, homeopathy can improve the overall health of the farm, which will mean the farmer experiences less disease generally. A healthier, more vibrant cow is much less likely to be susceptible to TB.

Homeopathy has the potential, applied correctly, to not only treat symptoms but also to increase resilience and reduce susceptibility to disease.

TF: What should they take into account before they do so?

Seek advice and support. Do your research. Speak to other farmers using it with good results about how they integrate it into their health planning.

It is important also to get appropriate veterinary support. Contact the Irish Society of Veterinary Homeopaths.

In the UK, there are no restrictions on farmers sourcing and using remedies in the UK. There are various useful remedy kits available. In Ireland, remedies must be sourced via a homeopathic vet.

There are hundreds of homeopathic remedies but some key ones that farmers use all the time are:

Farmers tend to use liquid remedies and spray bottles for ease of administration to individuals/groups or put remedies into the troughs if dosing the whole herd/flock.

This is difficult to quantify as every farm is different, and one farm may measure success by a different set of criteria than others.

However, our survey showed that 66% of farmers/71% of dairy farmers reported lower vet and medicine costs.

Sally Wood, who is a conventional turned organic farmer in Wales, told us:

I think the mainstream assumption is always that if you use homeopathy to reduce antibiotics, your welfare will go down and your cull rate will go up, but ours proved the opposite, and our herd is so healthy that we can sell our surplus stock.

When people ask me whether homeopathy works, I tell them that our vet and med bill has halved.

Interest appears to be growing. A group of homeopathic vets and farmers have done training together via NOTS, who all support one another in their learning.

Pat Ahernes Homeopathic Dairy Farm on Facebook is great for insight into how it can be used on the farm.

Anyone can start with a few simple remedies. (Obviously, farmers need to observe the regulations in their country and stay legal!)

We know some farmers who ONLY use the remedies Aconite and Arnica and report success.

Training and support are important for best results and to transform the health of a herd/flock. This is something that WHAg is dedicated to providing, including piloting a scheme to train farmers to provide coaching to other farmers.

This is not to replace the vet but to help them integrate strategies to foster health and resilience.

I think it is inevitable. People generally are taking a more holistic view on health.

Overall, we are more planet conscious. Furthermore, farmers are exploring less toxic health options such as fermented foods, herbs and homeopathy.

Also, Antimicrobial Resistance (AMR) is not going away; farmers are under a lot of pressure to reduce antibiotics.

In the UK, we see buyers and supermarkets leading the trend for reduction in antibiotics, and some organic milk buyers expect members to achieve PWAB status (Produced Without Antibiotics).

In conclusion, homeopathy and other non-toxic inputs such as ferments, herbs etc., offer a viable alternative for farmers.

For more information on WHAgs new learning and membership platform, and to sign up to our newsletter: see http://www.wholehealthag.org

See Facebook The Farmacy at WHAg

To share your story with Thats Farming, email catherina@thatsfarming.com

View original post here:
Homeopathic remedies that cattle farmers can use - Thats Farming

The research analysis of Healthcare Nanotechnology (Nanomedicine) market offers significant information regarding the major trends that define this business landscape with regards to the regional outlook and competitive scenario. The report also highlights the limitations & challenges that could hamper the industry remuneration alongside the key opportunities that will aid in business expansion. Moreover, the document provides crucial insights regarding the effect of COVID-19 pandemic on the overall market outlook.

This report contains market size and forecasts of Healthcare Nanotechnology (Nanomedicine) in Global, including the following market information:Global Healthcare Nanotechnology (Nanomedicine) Market Revenue, 2016-2021, 2022-2027, ($ millions)Global top five companies in 2020 (%)

The global Healthcare Nanotechnology (Nanomedicine) market was valued at 200560 million in 2020 and is projected to reach US$ 285060 million by 2027, at a CAGR of 9.2% during the forecast period.Research has surveyed the Healthcare Nanotechnology (Nanomedicine) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Download PDF Sample of Healthcare Nanotechnology (Nanomedicine) Market report @ https://www.themarketinsights.com/request-sample/253870

Total Market by Segment:Global Healthcare Nanotechnology (Nanomedicine) Market, By Type, 2016-2021, 2022-2027 ($ millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Type, 2020 (%)NanomedicineNano Medical DevicesNano DiagnosisOther

China Healthcare Nanotechnology (Nanomedicine) Market, By Application, 2016-2021, 2022-2027 ($ millions)China Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Application, 2020 (%)AnticancerCNS ProductAnti-infectiveOther

Global Healthcare Nanotechnology (Nanomedicine) Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & Africa

Report Customization available as per requirements Request Customization@ https://www.themarketinsights.com/request-customization/253870

Competitor AnalysisThe report also provides analysis of leading market participants including:Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmitH& NephewLeadiant BiosciencesKyowa Hakko KirinTakedaIpsenEndo International

To Check Discount @ https://www.themarketinsights.com/check-discount/253870

Table of ContentChapter One: Introduction to Research & Analysis Reports

Chapter Two: Global Healthcare Nanotechnology (Nanomedicine) Overall Market Size

Chapter Three: Company Landscape

Chapter Four: Market Sights by Product

Chapter Five: Sights by Application

Chapter Six: Sights by Region

Chapter Seven: Players Profiles

Chapter Eight: Conclusion

Chapter Nine: Appendix9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Table and FigureTable 1. Healthcare Nanotechnology (Nanomedicine) Market Opportunities & Trends in Global Market

Table 2. Healthcare Nanotechnology (Nanomedicine) Market Drivers in Global Market

Table 3. Healthcare Nanotechnology (Nanomedicine) Market Restraints in Global Market

Table 4. Key Players of Healthcare Nanotechnology (Nanomedicine) in Global Market

Table 5. Top Healthcare Nanotechnology (Nanomedicine) Players in Global Market, Ranking by Revenue (2019)

Table 6. Global Healthcare Nanotechnology (Nanomedicine) Revenue by Companies, (US$, Mn), 2016-2021

Table 7. Global Healthcare Nanotechnology (Nanomedicine) Revenue Share by Companies, 2016-2021

Table 8. Global Companies Healthcare Nanotechnology (Nanomedicine) Product Type

Table 9. List of Global Tier 1 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 11. By Type Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 12. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 13. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 14. By Application Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 15. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 16. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 17. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 18. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2016-2021

Table 19. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2022-2027

Table 20. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 21. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 22. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 23. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 24. By Region Asia Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021 continued

About us.The Market Insights is a sister company to SI Market research and The Market Insights is into reselling. The Market Insights is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between. At The Market Insights, we give our clients the best reports that can be made in the market. Our reports are not only about market statistics, but they also contain a lot of information about new and niche company profiles. The companies that feature in our reports are pre-eminent. The database of the reports on market research is constantly updated by us. This database contains a broad variety of reports from the cardinal industries. Our clients have direct access online to our databases. This is done to ensure that the client is always provided with what they need. Based on these needs, we at The Market Insights also include insights from experts about the global industries, market trends as well as the products in the market. These resources that we prepare are also available on our database for our esteemed clients to use. It is our duty at The Market Insights to ensure that our clients find success in their endeavors and we do everything that we can to help make that possible.

Direct ContactJessica Joyal+91-9284395731 | +91 9175986728sales@themarketinsights.com

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Trend, Technology Innovations and Growth Prediction 2021-2027 The Manomet Current - The Manomet...

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ --The global regenerative medicine marketsize is expectedto reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Key Insights & Findings:

Read 273 page research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027", by Grand View Research

Furthermore,advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Grand View Research has segmented the global regenerative medicine market on the basis of product, therapeutic category, and region:

List of Key Players of Regenerative Medicine Market

Check out more studies related to Global Biotechnology Industry, conducted by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Go here to see the original:
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. - PRNewswire

The Latest research study released by DBMR Global Nanotechnology Market with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. The report shows market share, size, trends, growth, trends, applications, competition analysis, development patterns, and the correlations between the market dynamics and forecasts for 2020 to 2027 time-frames. The report aims to provide an overview of global Nanotechnology Market with detailed market segmentation by product/application and geography. The report provides key statistics on the Market status of the players and offers key trends and opportunities in the market. Research report has been compiled by studying the market in-depth along with drivers, opportunities, restraints & other strategies as well as new-developments that can help a reader to understand the exact situation of the market along with the factors that can limit or hamper the market growth and the report also has been updated with Impacts & effects of Coronavirus pandemic and how it has influenced consumer behavior& the growth of the market as well as industries.

The Global Nanotechnology Market is expected to reach USD 24.56 billion by 2025, from USD 7.24 billion in 2017 growing at a CAGR of 16.5% during the forecast period of 2020 to 2025

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanotechnology-market&ab

Nanoscience is the study of extremely small things. The development of nanotechnology is being growing in many fields, as it has various applications, such as in chemistry, biology, physics, materials science and engineering. Nanotechnology deals with the use of nanoparticle of size of 1 to 100 nm to be used in all major field of medical. Materials designed from nanotechnology are lighter, stronger and more durable. In oncology research, nanotechnology assists in cancer eradication. Nanotechnology based device are also used in fitness monitoring. Smartphone apps and bracelets are developed based on nanotechnology concept. A nano based device is used to sense the body temperature, heartbeat and others which are sent back to the reader. After analysing the temperature and heartbeat, medical staff monitors the condition. All these nano based devices helps to drive the market. For elder people, battery-free printed graphene sensors are also developed which helps in gathering the health condition of the elder population, enables remote healthcare and improves the quality of life. In diagnostic and prevention, nanotechnology plays a vital role in cancer diagnostics. Nanotechnology based devices can detects the biomarker produced by the circulating tumor cells (CTCs) on the onset of cancer. Based on nanotechnology, two main methods of circulating tumor cells (CTC) isolations are magnetic and microfluidic methods. In clinical development fluorescent nano sensors are used for in-vivo monitoring of biomarkers. Another application of nanotechnology is nanomedicine which has potential application in diagnosis and therapy medicine for regeneration of tissues and organs.

This Nanotechnology Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Nanotechnology Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this reportGlobal Nanotechnology Marketwill rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Nanotechnology Market includes comprehensive information derived from depth study on Nanotechnology Industry historical and forecast market data. Global Nanotechnology Market Size To Expand moderately as the new developments in Nanotechnology and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-nanotechnology-market?ab

Nanotechnology Market report provides depth analysis of the market impact and new opportunities created by theCOVID19/CORONAVirus pandemic. Report covers Nanotechnology Market report is helpful for strategists, marketers and senior management, And Key Players in Nanotechnology Industry.

List of Companies Profiled in the Nanotechnology Market Report are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanotechnology-market&Ab

Nanotechnology Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Nanotechnology market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Nanotechnology report comes into play.

The Segments and Sub-Section of Nanotechnology Market are shown below:

By Type (Nano composites, Nano materials, Nano tools, Nano devices, Others)

By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others)

By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others

Market Size Segmentation by Region & Countries (Customizable):

Key questions answered

What impact does COVID-19 have made on Global Nanotechnology Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Nanotechnology market?

What are the key concerns of the five forces analysis of the Global Nanotechnology market?

What are different prospects and threats faced by the dealers in the Global Nanotechnology market?

What are the strengths and weaknesses of the key vendors?

Market Segmentation: Global Nanotechnology Market

The global nanotechnology market is segmented based on product type, application, industry and geographical segments.

By Product Type (Nano Composites, Nano Materials, Nano Tools, Nano Devices, Others), By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others), By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Based on product type , the market is segmented into nano-composites and nano materials, nano tools, nano devices, and others. Nano-composites are further sub segmented into nanoparticles, nanotubes and nano clays. Nano materials are further sub-segmented into nano fibers, nano ceramic products and nano magnetics. Nano tools are further sub-segmented into nanolithography tools and scanning probe microscopes. Nanodevices are further sub-segmented into nanosensors and nanoelectronics.

On the basis of application, the market is further segmented into healthcare, environment, energy, food & agriculture, information & technology and others.

Based on industries, the market is segmented into electronics, cosmetics, pharmaceutical, biotechnology and others.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Strategic Points Covered in Table of Content of Global Nanotechnology Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Nanotechnology market

Chapter 2: Exclusive Summary the basic information of the Nanotechnology Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Nanotechnology

Chapter 4: Presenting the Nanotechnology Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Nanotechnology market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Nanotechnology Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read more:
Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 - The Market Writeuo - The...

DBMR has added a new report titled Global Nanomedicine Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Report performs the methodical and comprehensive market research study that puts forth the facts and figures linked with any subject about industry. It all-inclusively estimates general market conditions, the growth prospects in the market, possible restrictions, significant industry trends, market size, market share, sales volume and future trends. A team of skilled analysts, statisticians, research experts, enthusiastic forecasters, and economists work painstakingly to structure such a great market report for the businesses seeking a potential growth. A Global Nanomedicine Market analysis report is generated with the best and advanced tools of collecting, recording, estimating, and analyzing market data.

Major insights of the realistic Global Nanomedicine Market report are complete and distinct analysis of the market drivers and restraints, major market players involved like industry, detailed analysis of the market segmentation and competitive analysis of the key players involved. Market segmentation categorizes the market depending upon application, vertical, deployment model, end-user, and geography etc. This global market document also presents an idea about consumers demands, preferences, and their altering likings about particular product. Furthermore, big sample sizes have been utilized for the data collection in the winning Global Nanomedicine Market report which suits the necessities of small, medium, as well as large size of businesses.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global Nanomedicine Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Nanomedicine Market is Expected to Grow at an Impressive CAGR by 2028 The Manomet Current - The Manomet Current

Rising investment in urgent care and increasing global geriatric population are key factors driving revenue growth of the global nanorobotics market

The globalNanorobotics marketsize is expected to reach USD 14.03 Billion in 2028 and register a CAGR of 10.9% over the forecast period, according to the latest report by Emergen Research. Nanorobotics market revenue growth is driven by key factors such as rapid innovations in nanorobotics technology and increasing application of the technology in treatment of neurological cardiovascular, oncological, infectious, orthopedic diseases, and others.

Nanorobotics is the technology which creates robots or machines at a very small scale. The field of nanorobotics brings together various disciplines, including nanofabrication processes used for producing nanoactuators, nanomotors, and nanosensors, among others. Rising focus on regenerative medicine coupled with technological advancements is boosting market revenue growth. Furthermore, increasing adoption of medical equipment and more advanced technologies such as Machine Learning (ML) and Artificial Intelligence (AI) is driving growth of the global nanorobotics market, and the trend is expected to continue going ahead.

Access full Report Description, TOC, Table of Figure, [emailprotected] https://www.emergenresearch.com/request-sample/744

Some Key Highlights From the Report

Key Growth Prospects:The report specializes in examining the major growth prospects of the global Nanorobotics market, such as new product launches, collaborations, joint ventures, mergers & acquisitions, agreements, partnerships, and the progress of the key market players functioning in the market, on regional and global levels.

The market intelligence report exhaustively examines the market value, share, demand, growth prospects, latest and historical trends, manufacturers, gross revenue collection, competitive terrain, market growth forecast, available products, and end-use applications.

Geographical Terrain of the Global Nanorobotics Market:

Please connect with our representative to get a Inquiry Of the Nanorobotics [emailprotected] https://www.emergenresearch.com/request-sample/744

For the purpose of this report, Emergen Research has segmented the global nanorobotics market based on type, application, and region:

To Get This Report At A Profitable [emailprotected] https://www.emergenresearch.com/request-discount/744

Table Of content

Chapter 1. Market Synopsis 1.1. Market Definition 1.2. Research Scope & Premise 1.3. Methodology 1.4. Market Estimation TechniqueChapter 2. Executive Summary 2.1. Summary Snapshot, 2020-2028Chapter 3. Indicative MetricsChapter 4. Nanorobotics Market Segmentation & Impact Analysis 4.1. Nanorobotics Market Material Segmentation Analysis 4.2. Industrial Outlook 4.2.1. Market indicators analysis 4.2.2. Market drivers analysis 4.2.2.1. Rising Focus on Nanotechnology and Regenerative Medicine 4.2.2.2. Increasing Government Support and Level of Investment in Nanorobotics 4.2.3. Market restraints analysis 4.2.3.1. Implementation of Excise Tax and Heavy Custom Duty on 4.3. Technological Insights 4.4. Regulatory Framework 4.5. ETOP Analysis 4.6. Porters Five Forces Analysis 4.7. Competitive Metric Space Analysis 4.8. Price trend Analysis 4.9. Customer Mapping 4.10. Covid-19 Impact Analysis 4.11. Global Recession Influence

Chapter 5. Nanorobotics Market By Type Insights & Trends 5.1. Type Dynamics & Market Share, 2021 & 2028 5.2. Nanomanipulator 5.2.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3. Electron Microscope (EM) 5.2.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.3. Scanning Electron Microscope (SEM) 5.2.3.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.4. Transmission Electron Microscope (TEM) 5.2.3.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4. Scanning Probe Microscope (SPM) 5.2.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.3. Atomic Force Microscopes (AFM) 5.2.4.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.4. Scanning Tunneling Microscope (STM) 5.2.4.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.2.4.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.3. Bio-Nanorobotics 5.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.4. Magnetically Guided 5.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.5. Bacteria-Based 5.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Chapter 6. Nanorobotics Market By Application Insights & Trends 6.1. Application Dynamics & Market Share, 2021 & 2028 6.2. Nanomedicine 6.2.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.3. Biomedical 6.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.4. Mechanical 6.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.5. Others (Space and Oil & Gas) 6.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Continue..!

Request customization of the report: https://www.emergenresearch.com/request-for-customization/744

Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you a report well-suited to your requirements.

Media ContactCompany Name: Emergen ResearchContact Person: Eric LeeEmail: Send EmailPhone: +1 (604) 757-9756Address:14671 110 Avenue Surrey, British Columbia, V3R2A9City: SurreyState: British ColumbiaCountry: CanadaWebsite: http://www.emergenresearch.com/industry-report/nanorobotics-market

Read the original post:
Nanorobotics Market By Player, Region, Type, Application And Sales Channel, Regions, Type and Application, Revenue Market Forecast to 2028 - Digital...